In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...
The global Platelet Aggregation Devices Market is valued at USD 590.65 Million in 2024 and is projected to reach a value of USD 1086 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 5.75% ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results